Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05056051 · ClinicalTrials.gov registry record · NA
Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus
A NA study of Esophageal Cancer and Barrett Esophagus, sponsored by Northwestern University.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 4
- Study locations
NCT05056051 is a NA study of Esophageal Cancer and Barrett Esophagus that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 200 participants, below the 497-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (60% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05056051, a NA study of Esophageal Cancer and Barrett Esophagus, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 4
- Study locations
Study Summary
Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barrett's esophagus recurrence following treatment. Wide-Area Trans-Epithelial Sampling (WATS-3D) is a new technology that uses brush sampling to examine larger areas of the esophagus as compared to conventional biopsies. Preliminary studies show improved detection of cancerous changes in Barrett's esophagus surveillance. The investigators hope to see if the addition of WATS-3D increases the rate of detection of recurrent BE following treatment, which is of the utmost importance since it would allow for earlier re-treatment of disease and ultimately allow for prevention of progression to esophageal cancer.
Conditions Studied
Interventions
- DEVICE WATS-3D tissue sampling prior to forceps biopsies
- DEVICE WATS-3D tissue sampling following forceps biopsies
Study Locations (4)
California
- University of California, LA - Los Angeles
Colorado
- University of Colorado - Aurora
Illinois
- Northwestern Memorial Hospital - Chicago
Missouri
- Washington University in St. Louis, Barnes Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2020-10-01 |
| Est. Completion | 2025-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05056051
The ClinicalTrials.gov registry entry for NCT05056051 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 497-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (60% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 2 interventions - of which WATS-3D tissue sampling prior to forceps biopsies is the first listed.
NCT05056051 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Illinois.
Frequently Asked Questions
What is clinical trial NCT05056051 about?
NCT05056051 is a clinical study titled "Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus". Esophageal cancer is a deadly disease that is becoming increasingly common in the United States. Barrett's esophagus (BE) is a pre-cancerous state that can develop into esophageal cancer, but is highly treatable. Progression of BE to esophageal cancer is still common due to missed diagnosis of Barre...
What is the current status of trial NCT05056051?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2020-10-01. Estimated completion is 2025-06-30.
What conditions does trial NCT05056051 study?
This clinical trial studies the following conditions: Esophageal Cancer, Barrett Esophagus.
What interventions are being tested in trial NCT05056051?
The interventions under investigation include: WATS-3D tissue sampling prior to forceps biopsies (DEVICE), WATS-3D tissue sampling following forceps biopsies (DEVICE).
Who is sponsoring clinical trial NCT05056051?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05056051 being conducted?
This trial has 4 study locations across California, Colorado, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Prehabilitation in Oncology Via Exercise- Esophageal (IMPROVE-Esophageal)
RECRUITING · NA
-
Exercise Prehabilitation for Locoregional Esophageal Cancer
RECRUITING · NA
-
Resilience and Equity in Aging, Cancer, and Health (REACH)
RECRUITING · NA
-
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
RECRUITING · NA
-
Serial MRI Scans During Radiation Therapy
RECRUITING · NA
-
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.